Abstract 1680P
Background
Chronic pain is reported by > 50% of patients recovering from breast cancer (BC). Adverse life experiences (ALEs) are associated with decreased psychosocial functioning in BC survivors, but their effect on pain has not been thoroughly explored. Sense of coherence (SOC) is the disposition to feel that life is predictable and manageable. Sense of danger (SOD) reflects expectations of harm from a particular event.
Methods
We are conducting a prospective study to assess if ALEs increase chronic adverse effects in patients with localized BC and identify mediating mechanisms. Patients are recruited before starting (neo)adjuvant oncological treatment and assessed periodically by validated questionnaires, including ALEs, SOC, SOD from BC, FACT-COG, FACT-ES, and brief pain inventory. Blood samples for inflammatory biomarkers are stored. This sub-study tested if ALEs are associated with baseline pain, measured as a composite score of pain intensity and interference, and examined the mediating role of SOC and SOD.
Results
Of 126 participants, 97 provided data on ALEs. Median age was 49 (range 23-75). 53.6% were treated in the neoadjuvant setting. Chemotherapy was planned for 62.9%. More ALEs correlated with more pain (r =. 34, p <. 001). Educational level and planned chemotherapy correlated with less pain. Serial mediation analysis revealed that after controlling for these variables, ALEs were indirectly associated with more pain through lower SOC followed by higher SOD from BC, CIs = 0.001, 0.103. Together, the model explained 38% of the variance in patients’ pain, F (5, 82) = 9.92, p <. 001. Age, BMI, CRP levels, and neutrophils to lymphocytes ratio were not associated with pain scores or with other study variables. Having surgery (vs planned surgery) was not associated with pain scores.
Conclusions
Exposure to a higher number of ALEs was associated with higher baseline pain in early BC patients before oncological treatment, mediated by decreased SOC and higher SOD from BC. These results stress the importance of addressing past trauma, sense of coherence, and sense of danger from BC to improve physical adverse effects such as pain. Further study will explore the effect of ALE, SOC, and SOD on pain persistence after adjuvant therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1646P - A multicohort phase II trial of androgen deprivation therapy (ADT), docetaxel (DOCE) and nivolumab (NIVO) in patients (pts) with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) enriched for inflamed tumours and DNA damage repair (DDR) alterations: Cohort 3 results
Presenter: Xiao Wei
Session: Poster session 11
1647P - Clinical validity of plasma DNA testing to identify BRCA-mutated (BRCA+) patients in the MAGNITUDE study
Presenter: Gerhardt Attard
Session: Poster session 11
1649P - Impact of concomitant medications on safety in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC) receiving rezvilutamide (Rez) plus androgen-deprivation therapy (ADT): A post-hoc analysis of the randomized phase III CHART trial
Presenter: Dingwei Ye
Session: Poster session 11
1650P - Fuzuloparib plus abiraterone acetate and prednisone (AA-P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A phase I study
Presenter: Tao Dai
Session: Poster session 11
1651P - Characteristics, tolerance and effectiveness of patients aged more or less than 75 years treated with [177Lu]Lu-PSMA-617 as part of France’s early access program
Presenter: David Tonnelet
Session: Poster session 11
1652P - SAABR: Single arm phase II study of androgen receptor pathway inhibitor (ARPI) + atezolizumab + GnRH analog (ADT) and stereotactic body radiotherapy (SBRT) to the prostate in men with de novo hormone-sensitive metastatic prostate cancer (mHSPC)
Presenter: Dana Rathkopf
Session: Poster session 11
1653P - Molecular and immunologic correlates of high PSMA/FOLH1 mRNA expression in prostate cancer (PC)
Presenter: Rana McKay
Session: Poster session 11
1654P - TAMARACK: Randomized Phase II trial of the B7-H3 targeting antibody drug conjugate (ADC) vobramitamab duocarmazine (vobra duo) in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Johann de Bono
Session: Poster session 11
1655P - Association of location of BRCA1/2 pathogenic variants with benefit from PARP-inhibitors in metastatic castration-resistant prostate cancers: Results from the PROGRESS study
Presenter: Lorena Incorvaia
Session: Poster session 11